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lymphoma and testicular cancer cells
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Abstract
It is of clinical importance to identify biomarkers predicting the efficacy of DNA damaging drugs (genotoxins) so that
nonresponders are not unduly exposed to the deleterious effects of otherwise inefficient drugs. Here, we initially
focused on the bleomycin genotoxin because of the limited information about the genes implicated in the sensitivity
or resistance to this compound. Using a whole-genome CRISPR/Cas9 gene knockout approach, we identified ASH2L, a
core component of the H3K4 methyl transferase complex, as a protein required for bleomycin sensitivity in L1236
Hodgkin lymphoma. Knocking down ASH2L in these cells and in the NT2D1 testicular cancer cell line rendered them
resistant to bleomycin, etoposide, and cisplatin but did not affect their sensitivity toward ATM or ATR inhibitors. ASH2L
knockdown decreased cell proliferation and facilitated DNA repair via homologous recombination and
nonhomologous end-joining mechanisms. Data from the Tumor Cancer Genome Atlas indicate that patients with
testicular cancer carrying alterations in the ASH2L gene are more likely to relapse than patients with unaltered ASH2L
genes. The cell models we have used are derived from cancers currently treated either partially (Hodgkin’s lymphoma),
or entirely (testicular cancer) with genotoxins. For such cancers, ASH2L levels could be used as a biomarker to predict
the response to genotoxins. In situations where tumors are expressing low levels of ASH2L, which may allow them to
resist genotoxic treatment, the use of ATR or ATM inhibitors may be more efficacious as our data indicate that ASH2L
knockdown does not affect sensitivity to these inhibitors.
Introduction
Cancer is the second leading cause of death worldwide,
only surpassed by cardiovascular disease1. In high income
countries however, cancer is responsible for nearly twice
as many deaths as cardiovascular disease, with a global
trend toward cancer becoming the leading cause of death
worldwide2. One of the main anticancer therapeutic
avenues are represented by DNA damaging agents (also
called genotoxins)3. The anticancer properties of these
drugs were discovered in the 1940s. Genotoxins became
very popular in the 1960s and 1970s4. To this day, DNA
damage causing agents are the largest class of anticancer
drugs. They are used to treat lung, breast, bladder, sto-
mach, ovarian, testicular, and other cancers5. These gen-
otoxic agents work by activating an intricate series of
signaling pathways that, taken together, have been termed
the DNA damage response (DDR). In eukaryotes, the
DDR involves a tightly regulated series of transcriptional,
post-transcriptional and post-translational events that
have evolved to prevent transmission of damaged DNA to
daughter cells. Initially the cell cycle is stopped and the
DNA repair machinery is recruited to DNA lesions. If the
extent of DNA damage surpasses the cell’s DNA repair
abilities, additional pathways are activated that lead to cell
death via mitotic catastrophe, apoptosis or necrosis, the
ultimate outcome that is expected from genotoxins6–8.
Although these types of chemotherapy agents are used in
many standard therapy regimens that represent the gold
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standard of care at the moment, they are also highly
unspecific and almost always display systemic side effects
that can be life threatening9.
Here, we have focused our initial investigation on a
DNA damaging drug called bleomycin. This drug was
discovered in the 1960s and FDA approved in 1973. It
became very popular in oncology clinics due to its anti-
tumor activity and low myelosuppressive properties10,11.
Bleomycin is currently part of the gold standard therapy
for Hodgkin’s lymphoma (HL), testicular cancer (TC),
germ cell cancers and others but its mechanism of action
is still not fully understood12,13. Akin to other unspecific
chemotherapy drugs, bleomycin has severe side effects,
mainly pulmonary toxicity that can be lethal on its own.
Up to 46% of patients treated with bleomycin containing
therapies develop pulmonary complications14. These
complications can lead to the patient’s death in 1–4% of
cases15–18. We focused on this drug because of a knowl-
edge gap between the wide use of bleomycin in the clinic
and the limited information about the genes implicated in
the sensitivity or resistance to this compound. Here we
show that HL and TC cancer cells depleted of ASH2L
(Absent, Small, or Homeotic-Like 2) are more resistant to
bleomycin and other DNA damaging agents. ASH2L is
part of protein complexes responsible for the tri-
methylation of histone 3 at lysine 4 (H3K4me3). These
complexes are comprised of a catalytic subunit (either
MLL1, MLL2, MLL3, MLL4, hSET1A, or hSET1B) bound
to the integral core members of the complex (ASH2L,
RbBP5, WDR5, and DPY30)19. H3K4me3 is found mainly
at promoters of transcriptionally active genes. Some
promoters are marked by both H3K4me3, considered an
activation mark, and H3K27me3, considered a suppres-
sive mark. Although typically not expressed, these pro-
moters have been termed bivalent promoters, and were
proposed to be “poised” for rapid activation and deacti-
vation of gene expression20. Bivalent promoters have been
reported mainly in embryonic stem cells, and the genes
downstream of them are important in differentiation and
development21,22. Interestingly, bleomycin resistance in
ASH2L knockdown cells does not seem to be mediated
through changes in the gene expression, but rather
through a global decrease in H3K4me3 levels that prime
the chromatin for DNA repair. Within the context of
personalized cancer therapy, decreased ASH2L levels
could be used as a biomarker for predicting a poor
response to DNA damaging agent-based therapy.
Results
We conducted a whole genome CRISPR/Cas9 gene
knockout screen23,24 in the presence or in the absence of
bleomycin in L1236 HL cells. These cells are derived from
a type of cancer that is currently treated with bleomycin-
containing chemotherapy. MaGECK algorithm25 analysis
of our CRISPR/Cas9 screen showed that ASH2L-depleted
cells were enriched in the bleomycin-treated population
(Fig. 1a, Table S1). All six sgRNAs targeting ASH2L
present in our library were enriched in the population of
cells treated for 10 days with bleomycin when compared
to the untreated population cultured for the same period
of time (Fig. S1A). ASH2L mouse knockouts are early
embryonic lethal and the absence of ASH2L does not
allow embryonic stem cell survival. Heterozygote mice
present no abnormal phenotypes26. Blastocyst formation
proceeds apparently normally in the absence of ASH2L
but further development does not take place26. Invalida-
tion of ASH2L, or its binding partner DPY30, blocks
proliferation and differentiation in the hematopoietic
lineage27,28. The tolerance to ASH2L gene disruption
seems therefore to vary between cell types. If L1236 cells
tolerate a complete absence of ASH2L, recovery of
ASH2L-specific sgRNAs in the CRISPR/Cas9 screen
could have come from full knockout cells or from cells in
which only one ASH2L allele was disrupted. If L1236
cannot proliferate/survive in the absence of ASH2L, the
recovery of ASH2L-specific sgRNAs likely originated from
cells that still expressed some functional ASH2L as a
result of only one allele being disrupted or through non
frameshift mutations preserving some of the activity of
the protein.
In order to validate the results of the CRISPR/
Cas9 screen, we used an independent genetic approach
based on small hairpin RNAs (shRNAs) to investigate the
effect of ASH2L depletion on genotoxin-resistance. The
shRNA-mediated decrease in ASH2L protein levels in
L1236 cells was accompanied by H3K4 methylation
reduction (Fig. 1b). Although the most commonly
expressed ASH2L isoform has a theoretical molecular
weight of 60.2 kDa (NM_001105214.2), this protein is
commonly detected at 80 kDa29,30, possibly due to post-
translational modifications. ASH2L knockdown in L1236
cells resulted in increased survival in response to bleo-
mycin and to another genotoxin, etoposide, a topoi-
somerase II inhibitor (Fig. 1c–e).
In the absence of bleomycin exposure, the mere culture
for 10 days of the cell population expressing the sgRNA
library led to a decrease in abundance of ASH2L-targeting
sgRNAs (Fig. S1B). ASH2L-targeting sgRNAs were among
the top most depleted ones following a 10-day culture
period (Fig. S1C). This indicates that, in untreated cells,
the absence of ASH2L decreases the ability of the cell
population to expand, for example because of a reduced
proliferation potential. A decrease in cell proliferation
upon ASH2L depletion was indeed previously reported31.
We could reproduce the negative impact of ASH2L loss
on population growth using shRNA-mediated ASH2L
knockdown (Fig. 1f). Cells lacking ASH2L had a decreased
proliferation potential (Fig. 1g), indicating that the
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reduced population growth upon ASH2L silencing is, at
least partly, a consequence of decreased proliferation.
Regarding the cell cycle profile, ASH2L depleted L1236
cells displayed a slight decrease in the percentage of cells
in S-phase, and an increase in the percentage of cells
blocked in S-phase. Upon bleomycin treatment, there
were almost no cell cycle differences between control and
ASH2L knockdown cells (Fig. S1D).
Interestingly, none of the other genes that were detected
as important for optimal population growth (e.g., PFN1,
PPP4C, DUT, or RPLP0) (Fig. S1C) had the corresponding
sgRNAs significantly enriched in the bleomycin-treated
population (Table S2). This indicates that decreased
proliferation is not the main mechanism driving the
observed resistance to bleomycin upon ASH2L depletion.
One possibility that could explain the observed
bleomycin-resistance phenotype is that a decrease in the
H3K4me3 mark, which labels transcriptionally “open”
chromatin, results in higher proportion of hetero-
chromatin within the nucleus. This would make it more
difficult for bleomycin to access DNA and cause double
strand breaks. However, the levels of H3K9me3 and
H3K27me3, the main heterochromatin markers32, were
not changed upon ASH2L knockdown in L1236 cells (Fig.
S2A, B).
We also checked if overexpression of ASH2L had an
impact on L1236 cell survival upon genotoxin exposure or
on H3K4me3 levels but found none (Fig. S2D).
As stated above, H3K4me3 modification, which mainly
occurs on promoters, is considered a mark of tran-
scriptionally active open chromatin32. At first sight, it was
surprising that a protein required for this modification
ended up to be the top hit in a screen designed to identify
proteins modulating bleomycin sensitivity. While most
publications are focusing on H3K4me3 in the context of
transcription, there is evidence that this mark influences
the DNA repair ability of cells. Firstly, upon DNA break
induction, histone lysine demethylases are recruited to
damaged chromatin to remove the H3K4me3 mark33–35.
Secondly, Bayo et al. have elegantly shown that aug-
menting H3K4me3 levels in cancer cells decreases their
ability to repair DNA breaks efficiently, rendering cells
more sensitive to DNA damaging agents36. These studies
prompted us to investigate the cells’ ability to repair their
DNA upon ASH2L depletion. We used specifically engi-
neered U2OS cells that carry reporters for the two main
DNA repair pathways in mammalian cells: the DR-GFP
reporter, developed by Maria Jasin37, which measures
repair through homologous recombination (HR), and the
EJ5-GFP reporter, developed by Jeremy stark38, which
measures repair through nonhomologous end joining
(NHEJ). Figure 2a depicts how the reporters record these
two types of DNA repair. ASH2L knockdown and
reduction in H3K4me3 levels was achieved by transfecting
the two reporter cell lines with a pool of 30 ASH2L-
directed siRNAs (Fig. 2b). Upon induction of DNA
damage by I-SceI expression in the reporter cells lines, we
observed a slight but significant increase in both HR and
NHEJ repair efficiencies upon ASH2L silencing (Fig. 2c).
In accordance with the hypothesis that ASH2L is detri-
mental to DNA repair, endogenous ASH2L proteins were
found to be excluded from areas of laser-damaged DNA
(Fig. 2d and Fig. S2C).
We then tested if increased DNA repair activity is also
detected in L1236 cells subjected to the selection condi-
tions used in the CRISPR/Cas9 screen. Control and
ASH2L-knockdown cells were therefore incubated with
increasing bleomycin concentrations for one hour or for
48 h and the extent of DNA damage evaluated by mea-
suring phosphorylated H2A.X (γH2A.X) levels39. After 1 h
of bleomycin treatment, γH2A.X levels were similar
between control and ASH2L knockdown cells, indicating
similar DNA damage induction in the two cell types.
However, after 48 h, these levels increased more in control
cells compared to ASH2L knockdown cells (Fig. 2e),
supporting the notion that, like in U2OS cells, depleting
ASH2L in L1236 cells leads to increased DNA repair
capability.
As stated above, ASH2L is part of a protein complex
that is responsible for the methylation of histone 3 at
lysine 4. This chromatin modification is generally present
at the promoters of active genes40. We investigated the
possibility that knocking down ASH2L leads to a gene
expression signature responsible for the promotion of
(see figure on previous page)
Fig. 1 ASH2L depletion leads to resistance to genotoxins in Hodgkin’s lymphoma cells. A MaGECK-based sgRNA enrichment analysis of the
CRISPR/Cas9 whole-genome knockout screen results. The graph depicts the p value associated with the observed difference in sgRNA abundance
between untreated cells and cells treated with bleomycin (250 ng/ml) for 10 days. B Western blot depicting shRNA-mediated knockdown of ASH2L
and H3K4me3 levels. The arrowheads indicate the 2 ASH2L splice variants expressed in most tissues 91. C, D Control (shCtrl) and ASH2L knockdown
(shASH2L) L1236 cells were treated with increasing concentrations of bleomycin (panel C) or etoposide (panel D) for 3 days. The relative numbers of
cells in the wells were estimated by Presto-Blue assays. E ASH2L knockdown and control cells were treated with the indicated concentrations of
bleomycin for 72 h. The dead cells were stained with DAPI and then analyzed by flow cytometry. F ASH2L knockdown and control cells were plated
in 96-well plates and the relative number of cells was analyzed each day during 5 days. G Flow cytometry analysis of the DNA synthesis rate,
measured by BrdU pulse labeling, in control (shCtrl) and ASH2L knockdown (shASH2L) cells.
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DNA repair and resistance to genotoxic stress. There is
some evidence that points in this direction as ASH2L
interacts with p53 at the promoters of proapoptotic
genes41. Note, however, that the HL cell line in which we
performed our screen is TP53 null42. We performed three
independent transcriptomic analyses of control (shCtrl)
and ASH2L knockdown (shASH2L) L1236 cells. Upon
setting a threshold of false discovery rate (FDR) of 0.05
and fold change ≥2, we found 93 upregulated and 228
downregulated genes in cells in which ASH2L was
silenced compared to the control cells. The differential
expression analysis for 14,000 genes is provided in Table
S3. The majority of the upregulated genes were low
expressed genes (Fig. 3a). The top 40 upregulated genes
Fig. 2 (See legend on next page.)
Constantin and Widmann Cell Death and Disease         (2020) 11:1019 Page 5 of 16
Official journal of the Cell Death Differentiation Association
are shown in Fig. 3b and the top 40 downregulated genes
are shown in Fig. 3c. We performed a gene ontology (GO)
analysis on the genes that were upregulated and down-
regulated (FDR < 0.05 and fold change ≥ 2). The main
enriched GO term when analyzing the genes down-
regulated in the ASH2L knockdown cells was cell pro-
liferation regulation (Fig. 3d). This is in agreement with
the observation that these cells grow slower (Fig. 1f). No
enriched GO terms were found when analyzing the genes
that were upregulated upon ASH2L knockdown. These
data indicate that resistance to bleomycin observed upon
ASH2L depletion is not a consequence of increased
expression of genes involved in DNA repair.
Since the resistance to genotoxins observed after
ASH2L downregulation does not seem to be regulated
through changes in the transcriptome, we sought other
possible explanations. One possibility is that, upon DNA
breaks being sensed, H3K4 demethylases are recruited to
the lesion and remove this mark. Only then is the repair
machinery recruited and the break repaired through HR
or NHEJ. In recent years, a few studies have shown that
hindering the cells’ ability to remove the H3K4me3 mark
at areas of DNA damage results in a decreased ability of
cells to repair their DNA leading to subsequent sensitivity
to genotoxins33,34,36. Our results are in agreement with
these observations. We extend these findings by showing,
for the first time, increased DNA repair capabilities of
cells with diminished H3K4me3 and/or ASH2L levels.
One way to test the hypothesis that low levels of
H3K4me3 promote DNA repair is through overexpressing
a histone lysine demethylase, such as KDM5A43. Unfor-
tunately, we were unable to obtain stable expression of
KDM5A in cells using either retroviruses, inducible len-
tiviruses, or generation of stable cell lines through plasmid
integration. We could obtain KDM5A expression by
transfecting cells with KDM5A-expressing plasmids but
for this we had to use five times the usual amounts of
DNA during the transfection procedure (this “over”
transfection was obtained using 5 μg of DNA per well of
12-well plates containing 105 cells). This expression was
functional, as evidenced by decreased levels of H3K4me3,
but was very transient (Fig. S3).
Our data indicate that cells with reduced H3K4me3
levels have a selective advantage compared to normal cells
in repairing their DNA in response to genotoxin-induced
DNA breaks. This is in line with earlier studies showing
that a reduced ability to remove the H3K4me3 mark at
areas of DNA damage hampers the recruitment of repair
proteins, leading to subsequent sensitivity to genotox-
ins33,34,36. We can therefore predict that H3K4me3 levels
no longer influence cell survival when cells are prevented
from turning on the signals that bring DNA repair pro-
teins to sites of damaged DNA. This can be achieved
through inhibition of ATM or ATR, the two main DNA
lesion signaling kinases44. In the absence of ATM or ATR,
cells are blind to DNA damage and die from unrepaired
DNA breaks, through mitotic catastrophe for exam-
ple45,46. Figure 4 shows indeed that ASH2L-depleted cells
have no survival benefit when incubated with ATM or
ATR inhibitors (i.e., their IC50 values are similar to those
of the control cells).
We next focused on TC for which bleomycin is part of
the standard therapy (bleomycin, etoposide, and cispla-
tin). TC represents around 2% of the total number of
cancers in males and the most common malignancy in
males aged 15–34 years. The incidence of TC has doubled
in the past 40 years and continues to increase47,48. Due to
the external location of the affected organs and the
(see figure on previous page)
Fig. 2 ASH2L depletion facilitates DNA repair. A Schematic representation (not to scale) of the DR-GFP reporter (left) and EJ5GFP reporter (right).
The DR-GFP construct bears a cDNA encoding the full-length GFP that contains an I-SceI restriction site disrupting the reading frame and leading to a
premature stop codon. This cDNA is followed by a 5′- and 3′-truncated GFP fragment that does not contain the I-SceI restriction site. The sequences
of this fragment and the complementary region in the full-length cDNA are indicated by different shades of gray. When cells expressing this reporter
are transduced with a lentivirus encoding the I-SceI enzyme, the reporter is cleaved at the I-SceI site. The ensuing DNA repair by homologous
recombination removes the termination codon in the full-length cDNA allowing for the production of a functional GFP (green). The EJ5GFP bears a
puromycin resistance gene flanked by two I-SceI restriction sites. This gene is followed by a GFP-encoding cDNA. In cells expressing this reporter,
removal of the puromycin resistance gene is achieved by transduction with an I-SceI encoding lentivirus. The ensuing NHEJ-mediated repair brings
the promoter and the GFP cDNA close together, allowing for GFP production. B Western blot depicting siRNA-mediated ASH2L knockdown
efficiency in the U2OS DR-GFP and U2OS EJ5GFP reporter cell lines and the resulting decrease in H3K4me3. C U2OS DR-GFP and U2OS EJ5GFP cells
were transfected with control siRNAs or ASH2L-specific siRNAs for 48 h and then infected with an I-SceI endonuclease-carrying lentivirus. Forty-eight
hours post infection, the percentage of GFP-positive cells was quantitated by flow cytometry (four independent experiments; the horizontal bars
correspond to the medians). D Live U2OS wild-type cells were micro-irradiated using the laser of a confocal microscope. The cells were then fixed
and stained with the indicated antibodies. Nuclei were labeled with DAPI. White arrowheads mark the boundaries of the irradiation track. Scale bar:
10 µm. E L1236 cells were treated with 0, 0.06, 0.12, 0.25, 0.5, 1, or 2 µg/ml of bleomycin. Samples were harvested 1 h (left) and 48 h (right) post-
treatment. The cells were lysed and 7.5 µg of proteins were analyzed by Western blotting using the indicated antibodies. The quantitation from three
independent experiments are shown below the blots. The intensity of the γH2A.X bands were normalized to the corresponding β-actin signals and
then expressed as percentage of the value of control cells exposed to the highest concentration of bleomycin.
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generally positive response to chemotherapy, TC has one
of the highest cancer cure rates (approximately 95%)49.
Despite this high survival rate, there is a subset of patients
with poor or even absence of response to standard che-
motherapy50. There are currently no consensus bio-
markers for predicting the effectiveness of the standard
chemotherapy used to treat TC51. We transduced TC
NT2D1 cells with either control shRNA or an shRNA
targeting ASH2L and tested the effectiveness of the
knockdown and the subsequent H3K4me3 decrease in
these cells (Fig. 5a). Strikingly, ASH2L knockdown
NT2D1 cells were resistant to three of the main drugs
used in TC treatment (Fig. 5b). The observed resistance
correlated with decreased DNA damage after 48 h of drug
exposure, indicating more efficient repair of damaged
DNA in ASH2L-depleted cells (Fig. 5c). Similarly to
L1236 cells, overexpression of ASH2L in NT2D1 cells did
not change their sensitivity to bleomycin (Fig. S2E). We
also observed that NT2D1 cells were more sensitive to
bleomycin than L1236 cells. Therefore, we compared the
levels of ASH2L protein, in these two cell models. Inter-
estingly, the more sensitive NT2D1 cells exhibited
considerably higher levels of ASH2L than L1236 cells
(Fig. S5), further supporting the notion that lower levels of
ASH2L is associated with resistance to genotoxins41.
Due to the observed genotoxin resistance in ASH2L
knockdown cells, we checked if the available clinical data
support the idea that ASH2L levels represent a prognostic
Fig. 3 Transcriptome changes upon ASH2L depletion in L1236 cells. A Volcano plot showing on the x-axis changes in gene expression levels
and on the y-axis the p values associated with these changes. The average expression of the genes is indicated by a color code (see scale bar on the
right of the volcano plot). B, C Heatmaps depicting, according to fold changes, the top 40 downregulated (panel B) and upregulated genes (panel C)
with FDRs <0.05. Each column represents one independent experiment. D Gene ontology (GO) analysis of genes downregulated upon ASH2L
silencing (FDR < 0.05 and fold change ≥ 2).
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marker in TC patients. Using the Tumor Cancer Genome
Atlas (TCGA), available through the cBioportal website52,
we found no impact of ASH2L alterations on overall
cancer survival. However, TC patients carrying alterations
in the ASH2L gene were significantly more likely to
relapse, indicating that the first line of treatment was not
effective (Fig. 5d). The alterations were of various types,
one homozygous deletion, one missense mutation, and
one gene amplification. Consistent with this last case, our
results do not indicate that ASH2L overexpression
impacts resistance to treatment (Fig. S2D–E). Interest-
ingly, this patient presenting amplification of the ASH2L
gene (patient ID: TCGA-2G-AAF6), also presented a
KRAS G12V mutation, a mutation that is well-known to
negatively impact overall cancer survival and relapse53,54.
We hypothesize that the KRAS G12V mutation is the
cause of relapse in this particular patient, and not the
amplification of ASH2L gene. Unfortunately, this type of
data is not yet available for HL samples, preventing us
from testing whether ASH2L mutations are found asso-
ciated with this disease. Lastly, we checked if there was
any evidence of tumor samples that showed decreased
levels of ASH2L gene expression. Using TCGA data
analyzed through the GEPIA software55, we identified
ASH2L as being overexpressed at the mRNA level in TC
samples compared to normal tissues. Interestingly, some
TC tumor samples presented very low levels of ASH2L
mRNA, even below the levels detected in normal tissues
(Fig. 5e). According to our hypothesis, the minority of
patients with low ASH2L and/or H3K4me3 levels should
be treated with non-DNA damage-based therapy in order
for them not to suffer from the toxic side effects of
noneffective genotoxic drugs.
Discussion
The idea that cancer genome data can be used to predict
the response to therapy of an individual, and offer
potential guidelines to an optimal type of treatment, has
been postulated since the first sequencing of the human
genome56. This concept is supported by recent meta-
analyses of biomarker-based approaches in clinical
oncology showing significant improvement in efficacy and
overall death reduction caused by chemotherapy toxicity
when a personalized approach is used compared to a non-
personalized one57,58. Clinical oncologists generally agree
that there is an urgent need for new biomarkers to predict
the sensitivity or resistance to a particular treatment as
this is a major limiting factor for contemporary precision
medicine59. The results presented here indicate that
patients with low levels of ASH2L or H3K4me3 are more
likely to relapse when treated with DNA damaging
chemotherapy.
Although the overwhelming majority of studies inves-
tigating H3K4me3 modification do so from the perspec-
tive of transcription19,32,60, some recent studies have
focused on this modification in the context of DNA
damage. Enzymes responsible for removing this mark,
mainly members of the KDM5 family of proteins, are
recruited to damaged DNA. Knockdown of these proteins
decreases the ability of cells to repair their damaged
DNA33–35. Similarly, small molecule inhibitors of KDM5
enzymes increase the levels of H3K4me3 chromatin
modification, which in turn leads to impaired DNA repair
through both HR and nonhomologous end joining36,61.
Our data are in agreement with these observations. We
show that reducing the levels of H3K4me3 leads to
increase in both of these repair pathways (Fig. S6). In
Fig. 4 Effect of ASH2L depletion on ATM or ATR inhibition-induced death. Control (shCtrl) and ASH2L-silenced (shASH2L) L1236 cells were
incubated with increasing concentrations of the KU60019 ATM inhibitor or the AZ-20 ATR inhibitor for 72 h. The numbers of cells in the wells were
quantitated using the Presto-Blue assay. Three independent experiments were performed. The curves go through the median values. The
functionality of KU60019 is shown in Fig. S4. IC50 values correspond to the drug concentrations that intersect the curves halfway between the highest
and lowest y-axis values.
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accordance with this, we show that ASH2L, a core com-
ponent of the complex responsible for adding this chro-
matin mark, is excluded from areas of damaged DNA.
Although decreased levels of H3K4me3 have previously
been observed in areas of laser damaged DNA33, it was
not clear if this is only due to the recruitment of KDM5
enzymes or exclusion of the methylation complexes. Our
data indicates that both scenarios occur simultaneously.
In accordance with this model, Liu et al.62 have used
colorectal cancer tissue samples to show a correlation
between WDR82 protein levels, H3K4me3, and clinical
outcome. WDR82 is a noncore member of the ASH2L-
containing H3K4 trimethylation complex. Interestingly,
patients with low H3K4me3 levels showed less aggressive
tumors indicating low proliferation, but had a decreased
overall survival compared with the high-expression group.
One of the main avenues of treatment for colorectal
cancer is radiation therapy, which induces double-
stranded DNA damage. These observations are in line
with our data obtained in HL and TC cells.
Fig. 5 ASH2L depletion in the NT2D1 testicular cancer cell line leads to resistance to standard therapy. A Western blot depicting shRNA-
mediated ASH2L knockdown efficiency in NT2D1 TC cells. B Control and ASH2L-silenced NT2D1 cells were treated with the indicated drugs for 72 h.
The percentage of dead cells of three independent experiments was quantitated by flow cytometry following DAPI staining. The horizontal bars
correspond to the medians. C Control and ASH2L-silenced NT2D1 cells were treated with 0, 0.12, 0.25, 0.5, 1, or 2 µg/ml of bleomycin. One set of cells
was harvested at 1 h and the second set at 48 h post treatment. The cells were lysed and protein lysates analyzed by western blotting using the
indicated antibodies. D Testicular cancer patient survival (left) and relapse (right) graphs from the Tumor Cancer Genome Atlas (TCGA) database for
patients with (red line) or without (blue line) alterations in the ASH2L gene. Data obtained through the cBioportal website. Cohort name: Testicular
Germ Cell Tumors (TCGA, PanCancer Atlas). E Graph comparing ASH2L transcript levels between testicular cancer samples and normal testicular
tissue. The graph was generated through the GEPIA software. This tool requires a minimum fold change to be added to the analysis; here we used
1.74 (or log2FC= 0.8), which corresponds to situations where ASH2L expression is significantly upregulated in cancer vs tumor samples and the fold
change is at least 1.74. Dataset name: Testicular Germ Cell Tumors (TGCT). The zone shaded in gray corresponds to tumor cases where ASH2L levels
are much lower than what is found in control tissues.
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There is evidence, however, that points toward the exact
opposite role of H3K4me3 in cancer progression.
Decreased levels of H3K4 trimethylation levels have been
suggested to be beneficial in terms of therapeutic out-
come, for example in the case of pediatric ependymo-
mas63. Further investigations will elucidate whether these
discrepancies are due to differences between cancers
derived from different tissues, the type of treatment used
for these malignancies, or other factors.
It was surprising that no other core members of the
complex responsible for H3K4 trimethylation were
detected alongside ASH2L in our screen. Knockdown of
proteins such as WDR5 and DPY30 strongly decreases the
levels of H3K4me364,65. Hence, one could have expected
that depletion of these genes induces a phenotype similar
to what is observed upon ASH2L knockdown. However, a
previous study investigating the expression of MLL
complex components has shown that the four core
components are expressed at higher levels than the
methyltransferase subunits66. Possibly, these core com-
ponents have additional functions, independent of
H3K4 methylation. In the case of WDR5, transcription-
independent functions have been reported67,68. The
observation that, besides ASH2L, none of the other core
components are detected in our screen, raises the possi-
bility that ASH2L modulates the response to genotoxins
independently of H3K4me3.
Somewhat surprisingly, both WDR5 and DPY30
depletion display an opposite phenotype compared to the
one observed upon ASH2L knockdown. Downregulation
of WDR5 in colorectal cancer induces DNA damage and
chemosensitivity69, and knockdown of DPY30 increases
the levels of endogenous DNA damage and decreases the
DNA repair ability of hematopoietic stem cells70. WDR5
and DPY30 are required for the addition of H3K4me3.
One possible explanation for the different outcomes
observed upon WDR5, DPY30, and ASH2L invalidation
could be that ASH2L is the only core member of the
methyl-transferase complexes that is required for the
addition of the third methyl group. Unlike other core
members of these complexes, knockdown of ASH2L does
not affect the levels of H3K4me1 or H3K4me271,72. In
contrast, knockout of murine ASH2L or DPY30 also
induces a decrease in the levels of H3K4me2 and me127,28.
Our transcriptomic studies comparing control and
ASH2L knockdown cells have shown only mild changes in
overall gene expression. These changes were not asso-
ciated with biological processes involving cell death,
resistance to DNA damaging drugs, DNA repair, or other
biological pathways that could explain the resistance to
bleomycin. As H3K4me3 is present at the vast majority of
active promoters, decreasing its levels could have subtle
effects on transcription. These changes may not indivi-
dually be detected in our screen but the sum of numerous
subtle changes in gene expression brought by ASH2L
knockdown may turn out eventually to contribute to
genotoxin resistance.
We currently lack the tools to fully distinguish the roles
of each individual methyl group on histone 3 lysine 4.
Howe et al.71 argue that H3K4me3 is not required for, but
more a consequence of, efficient transcription, and that its
actual function remains enigmatic. In embryonic stem
cells, deletion of Cfp1, a component of Set1 complexes,
leads to a drastic decrease in the levels of H3K4me3.
Similar to our data, this has only a minimal effect on
overall transcription73. Moreover, treating embryonic
stem cells with doxorubicin, a DNA damaging drug, leads
to increased levels of H3K4me3 at hundreds of genes.
However, blocking H3K4me3 formation by removing
Cfp1 has almost no effect on gene expression, regardless
of doxorubicin addition74. Therefore, H3K4me3 seems to
be expendable for gene transcription and responsiveness.
Although we could not fully disentangle the relationship
between ASH2L, H3K4me3, and resistance to DNA
damaging agents, the results presented here clearly indi-
cate that low levels of ASH2L in cancer cells could be
used to predict genotoxin resistance but not resistance
to ATR inhibitors, which are in clinical trials at the
moment75.
Conclusion
ASH2L was initially regarded as an oncogene31. Our
study indicates that it can also act as a tumor suppressor
as its knockdown increases the resistance of tumor cell
lines treated with various genotoxins (bleomycin, etopo-
side, and cisplatin). However, ASH2L knockdown does
not confer resistance to ATR or ATM inhibitors. Patients
with low levels of ASH2L or H3K4me3 may be more likely
to relapse when treated with DNA damaging che-
motherapy but they should remain responsive to other
anticancer drugs such as ATM or ATR inhibitors. ASH2L




L1236 HL cells were purchased from DSMZ (ref: ACC
530) and grown in RPMI media. NT2D1 cells were pur-
chased from ATCC (ref: CRL-1973) and grown in DMEM
media. U2OS cells were purchased from ATCC (ref: HTB-
96). U2OS cells with stably integrated HR (DR-GFP) and
nonhomologous end joining (EJ5GFP) reporters were a
kind gift from the laboratory of Jeremy Stark (City of
Hope Comprehensive Cancer Center, CA 91010). U2OS
cells were grown in DMEM media. All cell culture media
was supplemented with 10% fetal bovine serum and
the cell lines were grown in 5% CO2 and a humidified
atmosphere.
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CRISPR/Cas9 whole-genome unbiased gene knockout
screen
L1236 cells stably expressing the Cas9 protein were
generated by transducing L1236 cells with viral particles
created with LentiCas9-Blast (see details below). The cells
were selected with 5 µg/ml blasticidin for 7 days. The
GeCKO v2 library was purchased from Addgene (two-
plasmid system catalog number 1000000049), and
amplified in bacteria as previously described76 and fol-
lowing the recommendations of the library creators77.
The library was packaged into viral particles (see lenti-
virus production section below). Then, we used 205 × 106
L1236 cells stably expressing the Cas9 protein for trans-
duction with the GeCKO viral library. Cells were plated at
a density of 3 × 106 cells per well of 12-well plates (in 3 ml
media) and immediately infected with concentrated virus
at a multiplicity of infection of 0.4 to insure that most cells
only expressed one sgRNA. Sixteen hours later, cells were
trypsinized, seeded in T150 flasks (200,000 cells/ml; 40 ml
per flask) and cultured in the presence of 1 µg/ml pur-
omycin to get rid of the non-infected cells. Seven days
later, 7 × 107 cells were harvested (“Time 0” sample), 7 ×
107 cells were left to grow untreated for 10 days (and
passaged as necessary), and 7 × 107 cells were grown for
10 days in the presence of 250 ng/ml bleomycin. The
bleomycin-containing medium was changed every other
day. The genomic DNA of the cells was extracted (see
section below) and used undiluted for polymerase chain
reaction (PCR) amplification using primers binding 5′ or
3′ of the sgRNA sequence integrated in the cell’s gen-
omes78. In a 50 µl reaction, 7 µg DNA was used as tem-
plate, 0.25 µM final primer concentration, and 25 µl of
NEBNext High Fidelity PCR Master 2× Mix (New Eng-
larnd Biolabs, M0541L). The primer sequences and their
description, along with the PCR program, are available in
Table S4. PCR amplicons were gel extracted (260 base
pair band) and sent for next generation sequencing at the
University of Lausanne, Genomic Technologies Facility
(https://wp.unil.ch/gtf). Differential sgRNA distribution
analysis between the control and ASH2L silenced cells
was performed using the MAGeCK algorithm25.
Genomic DNA extraction
Cells were washed once in cold phosphate-buffered
saline (PBS) and resuspended in lysis buffer (1% sodium
dodecyl sulphate (SDS), 50 mM EDTA, 50mM Tris, pH
8). For 3.5 × 107 cells, we used 6ml lysis buffer. Next, we
added 30 μl of 20 mg/ml proteinase K (Roche 03 115 828
001). The samples were incubated overnight at 55 °C.
Afterwards, 15 μl of 20 mg/ml RNase A (Roche
10109169001) was added to the samples that were then
quickly vortexed and incubated at 37 °C for 30 min, fol-
lowed by a 10 min incubation on ice. At this point, 2 ml of
cold 7.5M ammonium acetate was added to the samples
that were then vortexed for 15 s and centrifuged at 4000×g
for 10 min. The supernatant was transferred to a new tube
on which 6ml of isopropanol (100%) was added. The
tubes containing the samples were inverted 15–25 times
and then centrifuged at 4000×g for 10 min. The super-
natant was gently discarded and the remaining pellet was
washed once with 70% ethanol. The ethanol was removed
after an additional 4000×g centrifugation for 2 min and
the pellet was air dried for 5 min. The DNA pellet was
resuspended in 0.5 ml TE buffer (Sigma T9285) and
incubated at 65 °C for 1 h. The tubes were left to cool at
room temperature and then the DNA concentration was
measured via Nano-Drop apparatus (Thermo Fisher).
Western Blotting
Cells were harvested by trypsinization (attached cell
lines) or centrifugation (L1236 cells) and washed once
with cold PBS. The cell pellets were resuspended in cold
radioimmunoprecipitation assay buffer (20 mM Tris-Cl
pH 8.0, 1 mM EDTA, 1% Triton X-100, 1% sodium
deoxycholate, 0.1% SDS, 150mM NaCl) supplemented
with cOmplete protease inhibitor (Roche 11836145001)
and PhosStop (Roche 04906837001), for 30 min on ice
with occasional mixing. The samples were sonicated for
5 s at 40% amplitude using a Vibra-Cell 75186 machine.
The tubes were centrifuged at 14,000g, 4 °C for 10 min
and the supernatant was used for protein quantification
using the BCA method (Pierce 23225). Samples were
mixed with 2× Laemmli buffer and incubated for 10 min
at 95 °C. Thirty microgram of protein was loaded per lane
on either 15%, 10%, or 4–20% polyacrylamide gels. The
nitrocellulose membranes were blocked for 30 min at RT
with 5% bovine serum albumin (BSA) dissolved in TBST
solution. Antibodies were diluted (1:2000) in TBST with
5% BSA, and incubated overnight at 4 °C with gentle
shaking. Membranes were washed three times with TBST
and incubated with fluorochrome conjugated secondary
antibodies (Invitrogen, A21109, A21057, or A32735), for
1 h at room temperature. Membranes were then washed 3
times with TBST and scanned using a Lycor Odyssey
system. For signal quantification, a rectangular region was
drawn around a band of interest in the Lycor Odyssey
software, background was established by drawing an
identical region, in a portion of the blot with no visible
bands. The background signal was subtracted from the
band signal, and the values were used to make the graphs.
Presto-Blue cell number assay
We used the Presto-Blue viability (Thermo A13262)
reagent according to the manufacturer’s instructions.
Briefly, L1236 cells were plated at 2 × 103 cells per well of
96-well plates containing 100 μl of media per well. The
cells were then treated with the indicated doses of drugs
for 72 h. Presto-Blue reagent was added to each well
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(10 μl/well) and the plates were incubated for 2 h at 37 °C
and 5% CO2. The fluorescence was read at 560/590 nm
(excitation/emission) using a Cytation-3 plate reader. The
value of the blank samples (media with no cells but with
Presto-Blue) was deducted from all wells and the
remaining absorbance values were plotted in the graphs.
For the proliferation assay shown in Fig. 1f, control and
ASH2L depleted L1236 cells were plated in 96-well plates
at 1000 cells per well. Presto-Blue assay was performed
each day, from day 0 to day 6.
DAPI viability assay
Cells were plated in 12-well plates (4 × 104 for
NT2D1 cells, and 1 × 105 for L1236 cells) and treated with
genotoxins for the indicated amounts of time. Floating
and attached cells were harvested and incubated directly
(without washing) with DAPI (Thermo 62248) at a final
concentration of 1 μg/ml in the media they were grown in.
After 10 min the cells were analyzed on a CytoFlexS flow
cytometer, on the KO525 channel. A gate was placed
on the single cells, and subsequently on the DAPI-
positive cells.
5-bromo-2′-deoxyuridine (BrdU) incorporation assay and
propidium iodide cell cycle
L1236 cells were infected with control and ASH2L-
specific shRNA-encoding viruses and grown in the pre-
sence of doxycycline for 4 days in order for the knock-
down to occur (see the “shRNA-mediated knockdown of
ASH2L” section below). Thirty minutes before harvesting,
BrdU (10 μM final concentration) was added to the cell
cultures. Unless otherwise stated, the next steps were
performed at 4 °C. Two million cells were harvested and
washed with 1.5 ml PBS, and then resuspended in 300 μl
PBS. Next, 700 μl 100% ethanol was added to the tubes
under gentle vortexing to prevent clumping. The cells
were then kept overnight at 4 °C. The next day, the cells
were washed once with 1.5 ml of PBS and then incubated
in 500 μl 0.1M HCl, 0.5% Triton X‐100 in PBS for 10min.
The tubes were centrifuged at 170×g for 5 min (we
recommend a swing-out centrifuge for these samples, as
the cells can stick to the sides of the tubes in regular
angled centrifuges). The pellets were resuspended in
500 μl water, boiled for 10 min, and cooled down on ice
for 10min. Then, 1 ml of 0.5% Triton X‐100 in PBS was
added and the tubes were centrifuged as above. The pel-
lets were resuspended in 50 μl PBS containing 1% BSA
and 0.5% Tween and 1 μl of primary FITC-labeled anti-
BrdU antibody added to each sample. The tubes were
placed in the dark for one hour. Then, 1.45 ml of PBS was
added and the cells were centrifuged (170×g for
5 minutes), the pellets were resuspended in 500 μl PBS
containing 40 µg/ml propidium iodide and 200 µg/ml
RNase A. The tubes were incubated at 37 °C for 30min,
and then analyzed by flow cytometry using the FITC and
PE channels, of a FC-500 flow cytometer (Beckman
Coulter). All manipulations were performed in 1.7 ml
Eppendorf tubes. The data were analyzed as follows: a
gate was placed on single cells, and a second gate
(dependent of the first one) was placed on FITC-positive
(BrdU positive) cells. The geometric mean of all events in
the BrdU-positive gate was used to generate the graph in
Fig. 1g. For figure S1D, a gate was placed on single events,
and the rest of the gates are shown in the representative
example.
DNA repair reporter assays
The U2OS cells with stably integrated HR (DR-GFP)
and nonhomologous end joining (EJ5-GFP) reporters
were a kind gift from Jeremy Stark (City of Hope, Beck-
man Research Institute of the City of Hope, CA, 91010,
USA). These cells were plated in 6-well plates (8 × 104
cells/well) and immediately transfected with a pool of
control siRNAs or a pool of siRNAs targeting ASH2L (see
siRNA transfection protocol below). The next day, siRNA
transfection was repeated. On the following day, the cells
were transduced with a virus (multiplicity of infection of
1) carrying an I-SceI endonuclease gene. The next day,
media was changed and the cells were left to grow for
another 48 h period. The cells were then trypsinized and
washed once with PBS. One-quarter of the cells was used
for western blot analysis to check knockdown efficiency.
The rest of the cells was analyzed on a CytoFlexS flow
cytometer, gating on GFP-positive single cells.
RNA isolation and sequencing and analysis
L1236 harboring inducible shRNAs were plated at a 2 ×
106 cells per 10-cm plate density and stimulated 4 days
with 1 μg/ml doxycycline. The cells were washed twice in
cold PBS and total RNA was extracted using a High Pure
RNA isolation kit (Roche 11828665001). Reverse tran-
scribed RNA was used for sequencing by the University of
Lausanne, Genomic Technologies Facility. Fastq files were
demultiplexed and adapters were trimmed using Cuta-
dapt79. Fastq screen was used to remove ribosomal RNA
sequences. STAR80 was used to align the reads against the
Homo sapiens GRCh38.92 genome. Differential gene
expression was computed with limma81 by fitting the six
samples into a linear model and performing the com-
parison between shASH2L and shControl. As the
experiment was performed in batches and samples are
paired, pairing was corrected for in the linear model.
Moderated t test was used for the comparison between
shCtrl and shASH2L samples. In order to correct for
multiple testing, we used the Benjamini–Hochberg
method82 to calculate the FDR (also known as adjusted
p value). Heatmaps were generated from log2 expression
values, using the expression module of the heatmapper.ca
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online application. The Z score in the heat-maps is cal-
culated by subtracting the mean of the row from each
value and then dividing the resulting values by the SD of
the row. The GO analysis was performed using the online
Protein ANalysis THrough Evolutionary Relationships
(PANTHER) classification system developed by Huaiyu
et al.83.
Laser microirradiation
Wild-type U2OS cells were plated on glass bottom
35mm culture dishes (MaTek P35G-1.5-14-C) at a den-
sity of 5 × 105 cells per dish and incubated overnight. Ten
minutes before transporting the cells to the confocal
microscope, Live-Hoechst (Invitrogen H3570) was added
to the cells at a final concentration of 1 μg/ml. This allows
for the visualization of nuclei and also acts as a sensitizing
agent. The live cells were microirradiated using the
405 nm X-Cite light source and the fluorescence recovery
after photobleaching (FRAP) module of a Zeiss LSM 710
confocal microscope. Stripes within cells were irradiated
using 100% of the laser power (5 iterations, pixel dwell
time 50.1 μs). Fifteen minutes post irradiation, the cells
were washed once with PBS and then incubated with CSK
+ R buffer (10 mM Pipes, pH 7.0, 100 mM NaCl, 300mM
sucrose, and 3 mM MgCl2, 0.5% Triton X-100, and
0.3 mg/ml RNAse A) two times for 3 min at room tem-
perature to remove soluble proteins. The cells were then
washed once with 2 ml PBS and fixed with 4% paraf-
ormaldehyde for 15min. This was followed by two PBS
washes and the addition of 2 ml of PBS containing 5%
fetal bovine serum and 0.3% Triton X-100. The samples
were co-incubated with anti-ASH2L and anti phospho-
H2A.X antibodies diluted (according to their datasheet) in
PBS containing 1% BSA and 0.3% Triton X-100, overnight
at 4 °C. The next day, the plates were washed twice with
2 ml PBS and the secondary antibodies were added,
diluted in the same buffer. One hour later, the plates were
washed, and PBS containing 1 μg/ml Live-Hoechst was
added for 10 min at room temperature. The cells were
washed three times with PBS and glass coverslips were
mounted using VectaShield (Vector laboratories H-1000-
10), and sealed with nail polish. The next day, the dishes
were imaged using the same confocal microscope that was
used for the irradiation.
Lentivirus production
Low passage HEK 293T cells were plated (1 × 106 cells/
plate; in 10ml media) in 10 cm dishes, and left to adhere
overnight. The cells were transfected using the calcium
phosphate method84, with 7.5 μg psPAX2, 2.5 μg pMD2.
G, and 10 μg of specific cDNA or shRNA lentiviral-
encoding plasmids. Briefly, chloroquine (Sigma C6628)
was added to the media to a final concentration of 25 μM.
In a sterile tube, the DNA and sterile water were mixed to
a final volume of 450 μl. After the addition of 50 μl of
2.5M CaCl2 solution, the samples were mixed and incu-
bated 20min at room temperature. Then, 500 μl of a 2×
HEPES solution (NaCl 280 mM, KCl 10mM, Na2HPO4
1.5 mM, D-glucose 12 mM, HEPES 50mM) were added
and the tube contents were briefly mixed. One minute
after the HEPES buffer was added, the contents of the
tube were added dropwise to the cells. Eight hours later,
the media was changed and the cells were grown for 48
more hours. Next, the media was collected and cen-
trifuged at 2500 rpm for 5 min to remove floating cells.
The resulting supernatant containing the viral particles
was aliquoted and stored at −80 °C. Titration was per-
formed using puromycin selection of infected cells. Unless
specified otherwise, the minimal volume of viruses con-
ferring 100% protection against puromycin was used in
subsequent experiments.
siRNA transfection
U2OS cells were plated in 1ml of DMEM at 4 × 104 per
well in 6-well plates. The first round of siRNA transfec-
tion was performed right after the plating when the cells
were still floating. The transfection mix was made as
follows: 200 μl Opti-MEM (Thermo 11058021) were
added to a sterile 1.7 ml Eppendorf tube, then 1.2 μl of
siRNA (5 μM stock) was added, followed by 2 μl of
Lipofectamine RNAi-MAX (Invitrogen 13778-075). The
tube was gently mixed and incubated at room tempera-
ture for 15min. This mixture was added dropwise in the
well containing the cells. The next day the media was
replaced with 1 ml of fresh media and the transfection was
repeated one more time. The cells were analyzed 96 h
after the first transfection. The final siRNA concentration
in the media was 5 nM. The pools of 30 siRNAs targeting
ASH2L (ref# 9070), and the siRNA negative control (ref#
si-C005-NEG001, a pool of 30 nontargeting siRNA
sequences), were purchased from the siTOOLS Biotech
company.
shRNA-mediated knockdown of ASH2L
L1236 and NT2D1 cells were transduced with
doxycycline-inducible shRNA carrying lentiviruses at an
MOI of 0.5 (this was achieved with about 0.25ml of non-
concentrated viral supernatant added to 2ml of media
containing 106 cells). We checked via western blotting that
there was no ASH2L knockdown in the absence of dox-
ycycline. For knockdown experiments, 2 × 106 cells were
plated in 10 cm2 plates, and cultured in the presence of
1 μg/ml of doxycycline for 4 days. Afterwards, the cells
were recounted and plated for experiments in 6, 12, or
96-well plates, depending on the type of experiment per-
formed. The shRNA sequence targeting ASH2L was 5′-T
TTACCAAGAATACATCTC-3′ and the control shRNA
sequence was: 5′-CACACAACATGTAAACCAGGGA-3′.
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cDNA transfection
NT2D1 cells were plated in 12-well plates, at 1 × 105
cells per well, in 700 μl media, and left to adhere over-
night. The next day the media was changed for 700 μl
fresh media. In a sterile tube, 1 μg DNA was mixed with
100 μl Opti-MEM media, and 1 μl Lipofectamine 2000
(Invitrogen 11668-019) was added. The tube was gently
mixed and incubated at room temperature for 30min.
The mixture was added dropwise in the wells. The media
was changed the next day, and cells were analyzed 48 h
post transfection.
Antibodies
The antibody against ASH2L used for Western blots
was from Bethyl (A300-489; lot 2) and the one used for
immunocytochemistry was from Cell Signaling (CLS
D93F6; lot 1). The antibodies against H3K4me3 (Ab8580;
lot GR3264593-1), H3K9me3 (Ab176916; Lot
GR2318257-2), H3K27me3 (Ab192185; lot GR3264827),
and phospho-ATM at serine 1981 (Ab81292; lot
GR217573-6) were purchased from Abcam. The antibody
against phospho-H2A.X at serine 139 was acquired from
Milipore (5636; lot 2554898), and the one against beta
actin from Cell signaling (CLS4970; lot 14). Our anti
FLAG antibody was purchased from Sigma (F1804-1MG;
lot SLGB5673V). The FITC-labeled anti-BrdU antibody
was purchased from Thermo Fisher Scientific (11-5071-
42, lot 4315462)
Chemicals
The following chemicals were purchased from Sigma-
Aldrich: ATM inhibitor KU-60019 (SML1416-5MG),
ATR inhibitor AZ-20 (SML1328-5MG), bleomycin
(B8416), etoposide (E1383), doxycycline (D3072), cisplatin
(P4394), 5-Bromo-2′-deoxyuridine (B5002). Puromycin
was purchased from Thermo-Fisher (A1113802), blas-
ticidin S was purchased from Carl Roth (CP14.2).
Statistical analysis
For the dose–response curves, the area under the curve
(AUC) was calculated for each group (shCtrl and
shASH2L) on a linear scale. The resulting AUC values and
the standard errors were used to perform an unpaired t
test between the two groups. The “n” for the t test was not
3. The “n” was equal to the degrees of freedom (df) of each
curve. The df was calculated as follows: number of data
points used for one curve (27) minus the number of
concentrations (9)+ 1 (because the t test subtracts 1
automatically). All calculations were performed in
GraphPad 8 software (La Jola, California, USA) according
to AUC statistics module and validated by the University
of Lausanne Biostatistics platform (https://wp.unil.ch/
biostatistics/). The same analysis was done for the
growth curve in Fig. 1f, and the WB quantification in Fig.
2e. For Fig. 1e and S2D, we performed unpaired t tests,
and the p values were corrected for multiple testing with
the Benjamini and Hochberg method. For Figs. 1g, 2c, 5b,
S2E, and S5 we performed two-tailed unpaired student’s
t tests. At least three independent experiments were
performed. Data are shown as median together with the
individual measurements.
Plasmids
LentiCas9-Blast (#849) is a third generation lentiviral
vector expressing the human codon-optimized S. pyogenes
Cas9 protein (tagged at the C-terminus with FLAG) and
blasticidin (both genes driven by the EFS-NS promoter).
This plasmid was a gift from Feng Zhang (Addgene
plasmid # 52962; http://n2t.net/addgene:52962; RRID:
Addgene_52962)85.
The pcDNA3 plasmid (#1) is a mammalian, CMV-dri-
ven, expression vector.
The hASH2L.dn3 (#1055) pcDNA3-based plasmid encodes
the human ASH2L 80 kDa isoform (NM_001105214.2), the
most commonly expressed isoform in cells and tissues. This
plasmid was a gift from Kai Ge (Addgene plasmid #15548;
http://n2t.net/addgene:15548; RRID:Addgene_15548)86.
The pLentiPURO-tetO-V5-6xHis (#980) is a lentiviral
backbone for mammalian expression of cDNAs. This plas-
mid was a gift from Ie-Ming Shih (Addgene plasmid # 39481;
http://n2t.net/addgene:39481; RRID:Addgene_39481)87.
The hASH2L.plp (#1052) is a hASH2L-encoding lenti-
viral vector. The plasmid was made by cutting out the
hASH2L insert from hASH2L.dn3 (mentioned above,
#1055) using BamHI and XhoI and ligating it into the
receiving lentiviral vector (pLentiPuro) opened with the
same enzymes.
The HA-Flag-hKDM5A (with intron 27).dn3 (#1048)
was a gift fromWilliam Kaelin (Addgene plasmid # 14799;
http://n2t.net/addgene:14799; RRID:Addgene_14799)88. It
expresses an N-terminally HA- and FLAG-tagged human
lysine demethylase KDM5A in the pcDNA3 backbone.
Sequencing this plasmid revealed the presence of 82 base
pairs of intron 27 before the last exon of the codon
sequence. This plasmids encodes a functional protein
(https://www.ncbi.nlm.nih.gov/pubmed/17320163).
HA-NLS-scSceI-IRES-BFP.pCVL (#1053) plasmid
expresses the HA-tagged I-SceI-encoding sequence fol-
lowed by an IRES and the coding sequence for the Blue
Fluorescent Protein. There is a nuclear localization
sequence inserted between the HA tag and I-SceI. This
construct was a gift from Andrew Scharenberg (Addgene
plasmid #45574 http://n2t.net/addgene:45574; RRID:
Addgene_45574)89.
The shCtrl.lti (#1056) and shASH2L.lti (#1057) were pur-
chased from Horizon Discovery (VSC11655 and
V3SH11252-225078488, respectively). They code for shRNA
sequences (described above under the “shRNA-mediated
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knockdown of ASH2L” section) and Turbo-RFP that are
both under a doxycycline-inducible promoter.
The packaging vector psPAX2 (#842) and the envelope
vector pMD2.G (#554) were gifts from Didier Trono
(Addgene plasmids #12260 and #12259, respectively)90.
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